AKEBIA THERAPEUTICS, INC. financials

AKBA CIK 0001517022

Source: EDGAR filings · Built 2026-06-02T02:17:12Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 67.70M -40.69M -23.38M -73.27M -253.02M -110.70M
EBITDA 24.77M -12.97M -8.63M -79.13M -262.57M -375.75M
Working Capital 90.02M 32.92M 18.28M 55.65M 10.10M 184.29M
Net Debt -133.05M -4.23M 5.20M 9.32M -13.42M -102.40M
Gross Margin 83.29% 60.56% 61.90% 70.74% 28.81% -0.62%
Operating Margin 9.95% -31.51% -23.77% -27.62% -124.97% -128.23%
Net Margin -2.26% -43.33% -26.68% -32.22% -133.25% -130.61%
Return on Equity (ROE) -16.39% 141.12% 169.78% -1801.64% -381.07% -157.49%
Return on Assets (ROA) -1.42% -31.45% -21.48% -26.46% -53.28% -59.74%
Current Ratio 1.55× 1.41× 1.18× 1.43× 1.04× 1.98×
Debt-to-Equity 1.59× -0.97× -1.57× 19.08× 1.84× 0.52×
Effective Tax Rate -43.64% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Conversion Ratio -12.72× 0.59× 0.45× 0.78× 0.90× 0.29×
Accruals Ratio -0.19× -0.13× -0.12× -0.06× -0.05× -0.43×
SBC % of Revenue 4.78% 4.85% 4.79% 6.10% 10.74% 8.30%
CapEx Coverage 233.65× -1232.09× -641.70× -4287.54× -348.23×
Free Cash Flow Per Share $0.26 $-0.19 $-0.12 $-0.40 $-1.52 $-0.80

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/FCF 6.11×
FCF Yield 16.35%
EV / EBITDA 11.88×
P/S 1.81× 2.67× 1.24× 0.36× 1.89× 1.41×
P/B 13.10× 20.31× 5.41× 1.70×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 236.20M 160.18M 194.62M 292.48M 211.65M 294.64M
Cost of Revenue 39.46M 63.18M 74.15M 85.57M 150.67M 296.48M
Research and Development Expense 62.36M 37.65M 63.08M 129.99M 147.85M 218.49M
Selling, General and Administrative Expense 107.48M 106.55M 100.23M 138.60M 174.14M 154.10M
Operating Expenses 173.24M 147.47M 166.73M 287.69M 325.48M 375.99M
Operating Income (Loss) 23.50M -50.47M -46.26M -80.78M -264.50M -377.83M
Income Tax Expense (Benefit) 1.62M 0 0 0 0 0
Net Income (Loss) Attributable to Parent -5.34M -69.41M -51.92M -94.23M -282.02M -384.84M
Earnings Per Share, Basic $-0.02 $-0.33 $-0.28 $-0.52 $-1.70 $-2.78
Weighted Average Number of Shares Outstanding, Basic 257.16M 210.95M 187.47M 182.78M 165.95M 138.46M
Earnings Per Share, Diluted $-0.02 $-0.33 $-0.28 $-0.52 $-1.70 $-2.78
Weighted Average Number of Shares Outstanding, Diluted 257.16M 210.95M 187.47M 182.78M 165.95M 138.46M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 184.84M 51.87M 42.92M 90.47M 149.80M 228.70M
Assets, Current 252.96M 113.83M 118.15M 185.18M 271.15M 371.44M
Assets 376.56M 220.67M 241.70M 356.05M 529.35M 644.14M
Long-term Debt 48.25M 38.69M 34.68M 66.08M 97.54M 96.38M
Liabilities, Current 162.94M 80.91M 99.87M 129.54M 261.05M 187.15M
Long-term Debt, Excluding Current Maturities 48.25M 38.69M 17.18M 34.08M 0 96.38M
Liabilities 343.95M 269.86M 272.29M 350.82M 455.34M 396.52M
Stockholders' Equity Attributable to Parent 32.61M -49.19M -30.58M 5.23M 74.01M 244.35M
Common Stock, Shares, Outstanding 265.42M 224.85M 194.58M 184.14M 177.00M 148.07M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 67.99M -40.66M -23.38M -73.15M -252.97M -110.39M
Payments to Acquire Property, Plant, and Equipment 291.00K 33.00K 0 114.00K 59.00K 317.00K
Net Cash Provided by (Used in) Investing Activities -7.93M -33.00K 0 -114.00K 39.94M -40.00M
Net Cash Provided by (Used in) Financing Activities 72.93M 49.66M -25.21M 14.60M 133.73M 231.72M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AKBA CIK 0001517022), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NVEC

NVE CORP

WSBC

WESBANCO, INC.

EPM

EVOLUTION PETROLEUM CORP